Methods and compositions for blocking microbial adherence to eukaryotic cells
    1.
    发明授权
    Methods and compositions for blocking microbial adherence to eukaryotic cells 失效
    阻断微生物粘附于真核细胞的方法和组合物

    公开(公告)号:US07470434B1

    公开(公告)日:2008-12-30

    申请号:US11881622

    申请日:2007-07-28

    IPC分类号: A61K9/48 A61K9/20 A61K9/14

    摘要: A method of blocking microbial adherence to a eukaryotic cell surface in a mammal by applying a pharmacologically acceptable composition containing at least one compound selected from the group consisting of isoleucine, an active isomer thereof, and an active analog thereof, to said surface in a microbial blocking quantity. Also, compositions for achieving the above blocking of microbial adherence.

    摘要翻译: 一种通过将含有选自异亮氨酸,其活性异构体及其活性类似物的至少一种化合物的药理学上可接受的组合物施用于微生物的所述表面来阻断微生物粘附到哺乳动物中的真核细胞表面的方法 阻塞量。 而且,用于实现上述微生物粘附阻断的组合物。

    Inducible defensin peptide from mammalian epithelia
    3.
    发明授权
    Inducible defensin peptide from mammalian epithelia 失效
    来自哺乳动物上皮的诱导型防御素肽

    公开(公告)号:US5550109A

    公开(公告)日:1996-08-27

    申请号:US248016

    申请日:1994-05-24

    CPC分类号: C07K14/4723 A61K38/00

    摘要: The present invention relates to an inducible antimicrobial peptide designated lingual antimicrobial peptide (LAP) which has antibacterial and antifungal activity and which can be obtained from mammalian epithelium. The prepro- and the pro- precursors of LAP are also provided. The present invention also relates to cDNA encoding LAP, the prepro- precursor or the pro-lingual precursor. In addition, methods of treating microbial infection of the epithelia are provided. Such infections can be treated by contacting the epithelia with an antimicrobially effective amount of a purified mammalian epithelial LAP or by administering a component which cause endogenous production or up-regulation of LAP.

    摘要翻译: 本发明涉及一种具有抗菌和抗真菌活性并可从哺乳动物上皮获得的称为舌形抗微生物肽(LAP)的诱导型抗微生物肽。 还提供了LAP的前体和前体。 本发明还涉及编码LAP,前原体前体或原始前体的cDNA。 此外,提供了治疗上皮细胞感染的方法。 可以通过使上皮细胞与抗微生物有效量的纯化的哺乳动物上皮LAP接触或通过施用引起LAP内源性产生或上调的成分来治疗这种感染。

    Endopeptidase
    4.
    发明授权
    Endopeptidase 失效
    内肽酶

    公开(公告)号:US5518912A

    公开(公告)日:1996-05-21

    申请号:US132767

    申请日:1993-10-06

    摘要: There is provided by the invention a novel composition comprising, in at least partially purified form, an endopeptidase endogenous to biological cells. The endopeptidase is characterized by having a molecular weight of about 110,000 daltons as measured by SDS PAGE; by being substantially insensitive to PMSF, TPCK, E-64, leupeptin, bacitracin, phosphoramidon and pepstatin; by being substantially inhibited by EDTA and 1,10-phenanthroline; and by being capable of cleaving peptide substrates comprising an alpha helical structural of at least about twelve to fourteen amino acids wherein said helix has a hydrophobic face and a hydrophilic face, said cleavage occuring amino terminal to a lysine or arginine residue on the hydrophilic face positioned within the context of at least four nonpolar amino acids substantially aligned along the hydrophobic face of the helix.

    摘要翻译: 本发明提供了一种新颖的组合物,其至少部分纯化形式包含生物细胞内源的内肽酶。 内肽酶的特征在于通过SDS PAGE测量的分子量为约110,000道尔顿; 对PMSF,TPCK,E-64,亮抑酶肽,杆菌肽,磷酰胺和胃酶抑素基本不敏感; 通过被EDTA和1,10-菲咯啉基本上抑制; 并且通过能够切割包含至少约十二至十四个氨基酸的α螺旋结构的肽底物,其中所述螺旋具有疏水面和亲水性面,所述切割在位于亲水面上的赖氨酸或精氨酸残基处发生氨基末端 在至少四个非螺菌氨基酸的情况下,沿着螺旋的疏水性表面基本排列。

    Inducible defensin peptide from mammalian epithelia
    7.
    发明授权
    Inducible defensin peptide from mammalian epithelia 失效
    来自哺乳动物上皮的诱导型防御素肽

    公开(公告)号:US5656738A

    公开(公告)日:1997-08-12

    申请号:US451501

    申请日:1995-05-26

    CPC分类号: C07K14/4723 A61K38/00

    摘要: The present invention relates to an inducible antimicrobial peptide designated lingual antimicrobial peptide (LAP) which has antibacterial and antifungal activity and which can be obtained from mammalian epithelium. The prepro- and the pro- precursors of LAP are also provided. The present invention also relates to cDNA encoding LAP, the prepro- precursor or the pro-lingual precursor. In addition, methods of treating microbial infection of the epithelia are provided. Such infections can be treated by contacting the epithelia with an antimicrobially effective amount of a purified mammalian epithelial LAP or by administering a component which cause endogenous production or up-regulation of LAP.

    摘要翻译: 本发明涉及一种具有抗菌和抗真菌活性并可从哺乳动物上皮获得的称为舌形抗微生物肽(LAP)的诱导型抗微生物肽。 还提供了LAP的前体和前体。 本发明还涉及编码LAP,前原体前体或原始前体的cDNA。 此外,提供了治疗上皮细胞感染的方法。 可以通过使上皮细胞与抗微生物有效量的纯化的哺乳动物上皮LAP接触或通过施用引起LAP内源性产生或上调的成分来治疗这种感染。

    Method for inhibiting angiogenesis using squalamine and squalamine
steroid derivatives
    10.
    发明授权
    Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives 失效
    使用角鲨胺和角鲨烯类固醇衍生物抑制血管发生的方法

    公开(公告)号:US5721226A

    公开(公告)日:1998-02-24

    申请号:US478763

    申请日:1995-06-07

    摘要: A method of inhibiting angiogenesis in a patient includes administering to the patient an effective amount of squalamine or a pharmaceutically acceptable salt of squalamine. Alternatively, a compound according to the following Formula (III) (or a pharmaceutically acceptable salt thereof) can be administered: ##STR1## wherein Z.sub.5 is .alpha.-H or .beta.-H; each of the substituents Z.sub.7 is selected from the group of --H, --OH, --SH, --NH.sub.2, --F, --(C.sub.1 -C.sub.3)-alkyl, and --(C.sub.1 -C.sub.3)-alkoxy; and one of the substituents Z.sub.12 is --H and the other is --H or --OH. X' is a polyamine side chain of the formula --X.sub.1 --(CH.sub.2).sub.p --X.sub.2 --(CH.sub.2).sub.q --N(R.sup.II)(R.sup.III), wherein one of X.sub.1 and X.sub.2 is --N(R.sup.IV) and the other is selected from the group of --N(R.sup.V), --O, --S, and --CH.sub.2. R.sup.IV and R.sup.V are each --H or --(C.sub.1 -C.sub.3)-alkyl, p and q are each an integer of from 0 to 5 (but both are not 0). R.sup.II and R.sup.III in the formula for X' are each --H, --(C.sub.1 -C.sub.3)-alkyl, or --(CH.sub.2).sub.r --N(R.sub.10)(R.sub.11) wherein r is an integer from 2 to 5 and R.sub.10 and R.sub.11 are each --H or --(C.sub.1 -C.sub.3)-alkyl. R' in Formula (III) is --H or --(C.sub.1 -C.sub.3)-alkyl, and Y' is --(C.sub.1 -C.sub.10)-alkyl, unsubstituted or substituted with --CO.sub.2 H, --OH, --NH--SO.sub.2 CF.sub.3, --SO.sub.3 H, --PO.sub.3 H.sub.2, --OSO.sub.3 H, --CF.sub.3, --F, ##STR2##

    摘要翻译: 一种抑制患者血管发生的方法包括向患者施用有效量的角鲨胺或其药学上可接受的盐酸盐。 或者,可以施用根据下式(III)的化合物(或其药学上可接受的盐):其中Z5是α-H或β-H的:(III) 每个取代基Z7选自-H,-OH,-SH,-NH2,-F, - (C1-C3) - 烷基和 - (C1-C3) - 烷氧基; 取代基Z12中的一个为-H,另一个为-H或-OH。 X'是式-X1-(CH2)p-X2-(CH2)qN(RII)(RIII)的多胺侧链,其中X1和X2之一是-N(RIV),另一个选自 -N(RV),-O,-S和-CH 2的基团。 RIV和RV各自为-H或 - (C1-C3) - 烷基,p和q各自为0至5的整数(但均不为0)。 式中X'中的RII和RIII各自为-H, - (C1-C3) - 烷基或 - (CH2)rN(R10)(R11),其中r为2至5的整数,R10和R11为 -H或 - (C 1 -C 3) - 烷基。 式(III)中的R'是-H或 - (C 1 -C 3) - 烷基,Y'是 - (C 1 -C 10) - 烷基,未被取代或被-CO 2 H,-OH,-NH-SO 2 CF 3,-SO 3 H ,-PO 3 H 2,-OSO 3 H,-CF 3,-F,< IMAGE>